Tag

Opioid Alternative

All articles tagged with #opioid alternative

health2 years ago

"FDA Urges Immediate Action Against Dangerous Tianeptine Products"

The FDA is warning consumers against purchasing or using tianeptine products due to severe risks, including death, and lawmakers are calling for immediate action. Tianeptine, an antidepressant prescribed in other countries, is not approved for use in the US and is often sold illegally as a dietary supplement, posing serious health risks such as agitation, drowsiness, and even death. Lawmakers have urged the FDA to take action, and a company has voluntarily recalled its tianeptine products. The substance has been linked to numerous adverse events and deaths, and its availability in gas stations and convenience stores poses a significant risk, especially amid the ongoing opioid epidemic.

healthcare2 years ago

"Vertex's Non-Opioid Breakthrough Sparks Record High Amidst Opioid Crisis"

Vertex Pharmaceuticals reported positive Phase 2 study results for its pain drug aimed at treating diabetic peripheral neuropathy (DPN), a long-term complication of diabetes. The study showed a statistically significant and clinically meaningful reduction in patients' reported pain levels across all doses of the drug. More than 30% of patients achieved a 50% or greater reduction in pain, and the drug was well-tolerated with no serious adverse events. Vertex plans to advance the development of the drug and hopes it will become an alternative treatment to prescribing opioids for pain management. Vertex stock rallied over 7% on the news.

pharmaceuticals2 years ago

"Vertex's Groundbreaking Drug Targets Global Market Potential, Says Cramer"

CNBC's Jim Cramer highlights Vertex Pharmaceuticals as a company to watch, as it develops a non-opioid drug, VX-548, to treat acute pain. Vertex aims to create a new class of prescription medications that address the addictive potential of opioids. Late-stage study results for VX-548 are expected within the year. Analysts at Leerink Partners believe the investment community underappreciates the potential of VX-548, comparing it to the obesity market a few years ago. Cramer's Charitable Trust owns shares of Eli Lilly, which expects its drug Mounjaro to expand its approved uses to obesity by year-end.